Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Temperature InduCed K+ channel as a tool to treat neuropathic pain

Descripción del proyecto

Una herramienta novedosa para tratar el dolor neuropático

Nuestro cuerpo ha desarrollado una capacidad notable para detectar y responder ante los estímulos nocivos, lo cual es esencial para nuestro bienestar y supervivencia. En los casos de lesiones persistentes, las partes del sistema nervioso periférico y central de la vía de transmisión del dolor se alteran, lo que lleva a una afección conocida como dolor crónico. El proyecto TICK, financiado con fondos europeos, se centra en el dolor neuropático, un trastorno de hipersensibilidad en la que el encéfalo traduce estímulos no dolorosos como dolor. En el proyecto se propone un método novedoso para inhibir la activación de las células neuronales asociadas con el dolor, que se presenta como una innovación prometedora a la limitada eficacia de los fármacos dirigidos al sistema nervioso central contra el dolor crónico y neuropático.

Objetivo

Non-invasive Control of Neuronal Activity can in principle contribute to the medical treatment of pathologic states in which the electrical activity of neurons is impaired, as in seizures and in chronic pain (CP). To this end, we are developing and validating proteins regulated by non-toxic external stimuli that freely penetrate tissues. TICK (Temperature InduCed K+ channel) is a K+ Channel reversibly regulated by Temperature in a very narrow range (37-40 °C). The open channel drives a large K+ efflux that hyperpolarizes the neuronal cell and prevents action potential firing. The effect is reversible and the channel closes when the temperature drops below 40°C. The perfect match with the temperature requirement for humans, prompts us to consider TICK as a promising medical tool for neuronal inhibition, in the treatment of CP. Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks). CP is extremely hard to treat, with only about half of patients reporting adequate pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population, which leads the brain to interpret as pain normally non-painful stimuli. NP is difficult to treat and to diagnose, due to the large number of entities involved (cells, genes and proteins working in synergy). Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction and nausea, thus restraining their adoption for prolonged treatments. TICK has no side effects and also overcomes the unavoidable limit of similar optogenetic treatment previously proposed: the need of fiber optic implant to bring light. The first version of these channels, has already been tested preliminary on rats. During this project we plan to further validate the treatment and explore its commercial potential.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.

Para utilizar esta función, debe iniciar sesión o registrarse

Régimen de financiación

ERC-POC - Proof of Concept Grant

Institución de acogida

UNIVERSITA DEGLI STUDI DI MILANO
Aportación neta de la UEn
€ 150 000,00
Dirección
Via Festa Del Perdono 7
20122 Milano
Italia

Ver en el mapa

Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Beneficiarios (1)